GLYXAMBI®

The recommended dose is an once-daily pill with 2 dosage strengths in the morning.

GLYXAMBI® may be increased to 25 mg empagliflozin/5 mg linagliptin once daily for additional glycemic control.¹

GLYXAMBI® may be taken with or without food.¹

Assessment of renal function is recommended prior to initiation of GLYXAMBI® and regularly thereafter.¹

DOSING AND ADMINISTRATION INFORMATION

Dosing guidance in patients with renal impairment:

Assess renal function before initiating GLYXAMBI® and as clinically indicated

GLYXAMBI® is not recommended for use in patients with an eGFR less than
30 mL/min/1.73 m² and contraindicated in patients on dialysis.

Dose of GLYXAMBI® does not require adjustment in patients with an eGFR
≥ 30< ml/min/1.73 m².¹

 

Additional Dosing Guidance¹

• In patients with volume depletion, correct this condition before initiating GLYXAMBI®.

•  GLYXAMBI® is contraindicated in patients on dialysis; hypersensitivity to empagliflozin, linagliptin, or any of the excipients in GLYXAMBI®, reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred.

• A lower dose of insulin or insulin secretagogues (e.g. sulfonylureas) may be required to reduce the risk of hypoglycemia when used in combination with GLYXAMBI®.